What are the adverse reactions of Ustekinumab?

In clinical trials, patients tolerated ustekinumab (Ustekinumab) well, and most adverse events were mild in severity. The most common adverse reactions were headache and nasopharyngitis, and the most serious adverse reaction was severe allergic reaction. After ustekinumab was put on the market, adverse events such as allergic reactions and angioedema, rash and urticaria, opportunistic fungal infections and tuberculosis, posterior reversible encephalopathy syndrome, interstitial pneumonia, eosinophilic pneumonia and cryptogenic organizing pneumonia, pustular psoriasis, erythrodermic psoriasis, allergic vasculitis, etc. have also occurred.

In the clinical study of ustekinumab, warnings and precautions such as infection, malignant tumors, allergic reactions, posterior reversible encephalopathy syndrome, and non-infectious pneumonia have emerged. Before starting treatment with ustekinumab, doctors will evaluate the patient for tuberculosis infection and do not give ustekinumab to patients with active tuberculosis infection. Monitor patients receiving ustekinumab closely for signs and symptoms of active tuberculosis during and following treatment.

The generic drug Ustekinumab has been launched in China and is included in the medical insurance, and is only reimbursed for patients who meet the indications. The price of the 130mg/26ml intravenous injection preparation may be more than 5,000 yuan per box, and the price of the 90mg: 1.0ml*1 subcutaneous injection preparation may be more than 8,000 yuan per box. The price of the 130mg/26ml intravenous injection preparation of Ustekinumab sold overseas may be more than 2,000 US dollars per box, and the price of 45mg: 0.5ml*1 subcutaneous injection preparation per box may be more than 10,000 US dollars. There are currently no generic versions of ustekinumab produced in other overseas countries.